Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tallow derivative use regardless of country's TSE/BSE status recommended by FDA cmte.

This article was originally published in The Tan Sheet

Executive Summary

TALLOW DERIVATIVE SOURCE IRRESPECTIVE OF COUNTRY's BSE STATUS RECOMMENDED by a narrow vote by FDA's Transmissible Spongiform Encephalopathies Advisory Committee at a meeting in Bethesda, Md. April 15-16. The committee voted 6-5 to allow for the sourcing of tallow derivatives in drugs, nutritional supplements, foods and cosmetics "from any country, irrespective" of its bovine spongiform encephalopathy (e.g., "mad cow disease") status, Committee Chairman Paul Brown, MD, National Institute of Neurological Disorders & Stroke, stated. The advisory group's recommendation would reverse current FDA guidelines, which disallow bovine source materials for the manufacturing of tallow derivatives from countries where TSE/BSE occur.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088359

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel